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Department of Materials Sciences and Engineering, Johns Hopkins University, Baltimore, MarylandABSTRACT Isolated receptor tyrosine kinase transmembrane (TM) domains have been shown to form sequence-specific
dimers in membranes. Yet, it is not clear whether studies of isolated TM domains yield knowledge that is relevant to full-length
receptors or whether the large glycosylated extracellular domains alter the interactions between the TM helices. Here, we
address this question by quantifying the effect of the pathogenic A391E TM domain mutation on the stability of the fibroblast
growth factor receptor 3 dimer in the presence of the extracellular domain and comparing these results to the case of the isolated
TM fibroblast growth factor receptor 3 domains. We perform the measurements in plasma membrane-derived vesicles using a
Fo¨rster-resonance-energy-transfer-based method. The effect of the mutation on dimer stability in both cases is the same
(~1.5 kcal/mol), suggesting that the interactions observed in simple TM-peptide model systems are relevant in a biological
context.INTRODUCTIONReceptor tyrosine kinases (RTKs) are membrane proteins
that are critical for cell growth, differentiation, and survival
(1). They are single-pass receptors with extracellular (EC)
ligand-binding domains and intracellular domains with
kinase activity. Over the last decade, structures of isolated
soluble EC and kinase domains have been solved using
x-ray crystallography (2–7), and structures of isolated trans-
membrane (TM)-domain dimers have been determined by
NMR (8–11). These structures have greatly enhanced our
understanding of RTK function. However, the details behind
the signal transduction across the plasma membrane are still
unknown, partly due to the lack of full-length RTK
structures.
Recent work has shown that the isolated RTK TM
domains have a propensity to form dimers in membranes
(12–14), suggesting that RTK TM domains play an impor-
tant active role in RTK signaling. Yet sequence alterations
in the TM domains sometimes do not alter RTK signaling
(15). Questions therefore arise as to whether the behavior
of the isolated TM domains is the same as their behavior
within the full-length receptors. In particular, the large
glycosylated EC domains may affect the structure of the
TM-domain dimer or may prevent the close approach of
the two TM helices, despite the fact that their sequences
encode for sequence-specific dimerization. Thus, currently
it is not known whether studies of isolated TM domains
yield knowledge that is relevant to full-length receptors.
Of all RTKs, fibroblast growth factor receptor 3 (FGFR3)
is known as the receptor with the largest number of patho-
genic mutations in its TM domain (13,16). FGFR3 is a nega-
tive regulator of bone growth and is critically important forSubmitted March 7, 2013, and accepted for publication May 31, 2013.
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are gain-of-function mutations, known to overinhibit bone
growth and cause skeletal dysplasias or craniosynostoses
(18). In addition, the mutations linked to skeletal disorders
have also been identified as somatic mutations in epithelial
cancers (19). The very fact that mutations in FGFR3 TM do-
mains cause diseases strongly suggests that FGFR3 TM
domain is not a passive membrane anchor. Furthermore,
Fo¨rster-resonance-energy-transfer (FRET)-based measure-
ments have shown that the isolated FGFR3 TM domains
form sequence-specific dimers in lipid bilayers (20). Dimer
stabilities of ~2.8 kcal/mol were measured in palmitoyl
oleoyl phosphatidylcholine (POPC), POPC/palmitoyl oleoyl
phosphatidylserine, and POPC/Cholesterol bilayers (21,22).
One of the pathogenic mutations in FGFR3, A391E, is
known as the genetic cause for Crouzon syndrome with
acanthosis nigricans, characterized by premature ossifica-
tion of the skull and skin abnormalities (23). The stability
of the mutant TM-domain dimer was measured as
4.1 kcal/mol in lipid bilayers, and thus this mutation
was shown to increase the dimerization of the isolated
FGFR3 TM domain by 1.3 kcal/mol (21). Based on this
work, it was hypothesized that this mutation stabilizes the
receptor dimeric state in the absence of ligand. The mutant
full-length FGFR3 was shown to exhibit higher phosphory-
lation than the wild-type in live human embryonic kidney
(HEK) 293T cells, consistent with the hypothesis (24,25).
Despite all this work, however, there are no direct demon-
strations that the EC domain does not affect the behavior
of the TM domain within the full-length receptor dimer or
that the A391E mutation stabilizes the full-length receptor
dimer and the TM-domain dimer in the same way.
One way to assess whether the presence of the EC domain
alters the nature of the interactions between the TM domains
is to compare the magnitude of the effect of the mutation onhttp://dx.doi.org/10.1016/j.bpj.2013.05.053
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and the isolated FGFR3 TM domains. Quantitative measure-
ments of dimer stabilities for complex glycosylated proteins
are now feasible, without the need for their extraction,
purification, and reconstitution (26,27). Such measurements
utilize a FRET-based method and are carried out in plasma
membrane-derived vesicles that bud off cells as a result of
treatments that destroy the actin cytoskeleton (28–31).
Here, we use this method to quantify the effect of the
A391E mutation on the stability of FGFR3 dimers in the
presence of its large glycosylated EC domain, such that
this effect can be directly compared to results for the
isolated TM-domain dimer in lipid bilayers.EXPERIMENTAL METHODS
Plasmid constructs
The enhanced yellow fluorescent protein (EYFP) plasmid was received
from Dr. M. Betenbaugh (Johns Hopkins University, Baltimore, MD) and
pRSET-mCherry was obtained from Dr. R. Tsien (University of California,
San Diego, CA). The plasmid encoding human wild-type FGFR3 in the
pcDNA 3.1(þ) vector was a gift from Dr. D. J. Donoghue (University of
California, San Diego, CA). All of the plasmids used for mammalian
expression were constructed with the pcDNA 3.1(þ) vector (Invitrogen,
Carlsbad, CA). All primers were purchased from Invitrogen.
The receptors used for these experiments were truncated FGFR3 recep-
tors, with the intracellular domains substituted with fluorescent proteins
such that FRET can be used for detection of dimerization. In particular,
the wild-type plasmid encoded the 22-amino-acid signal peptide of
FGFR3 (MGAPACALALCVAVAIVAGASS), the EC and TM domains of
FGFR3, a (GGS)5 flexible linker, and a fluorescent protein, either EYFP
or mCherry (a FRET pair) (see Fig. 1). Details about the construction of
this plasmid are given in Chen et al. (26). The A391E mutation was engi-
neered in the wild-type plasmid for this work using a QuickChange muta-
genesis kit (Roche, Madison, WI).Cell culture and transfection
HEK293T cells were a kind gift from Dr. Denis Wirtz (Johns Hopkins
University). HEK293T cells were chosen for this study because the activ-
ities of wild-type and mutant FGFR3 have been studied previously in this
cell line (24,25,32). The cells were cultured at 37C with 5% CO2 for 24
h, and 3  105 cells were seeded in each well of a six-well plate. Transfec-
tion was carried out using Fugene HD transfection reagent (Roche Applied
Science, Basel, Switzerland) according to the manufacturer’s protocol.
Cells in each well were cotransfected with 3 mg DNA encoding either 1),
the wild-type FGFR3 construct tagged with EYFP or mCherry, or 2), the
mutant FGFR3 construct tagged with EYFP or mCherry. No expression
of FGFR3 in HEK 293T cells was detected via immunostaining or Western
blots unless the cells were transfected (33–35), demonstrating that HEK
293T cells do not express endogenous FGFR3.wild-type
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vesicles
Here, we used the vesiculation buffer developed by Scott (28), as this is the
only buffer that vesiculates HEK293T cells before their detachment from
the substrate. As discussed previously, the original vesiculation procedure
was modified by the addition of glycine to quench the formaldehyde in
the buffer after vesiculation is triggered (36). We have shown that the
interactions of wild-type FGFR3 and GpA in plasma membrane-derived
vesicles produced by this method are not affected by the formaldehyde
presence (37,38). In particular, we demonstrated that the measured FRET
efficiencies and dimeric fractions are the same in Chinese hamster ovary
(CHO) cells and A431 vesicles produced with this method and with an
osmotic vesiculation buffer we recently developed that contains salts but
no active chemicals (37,38).
Vesiculation was performed as described previously (28,30). HEK293T
cells were rinsed once with phosphate-buffered saline (PBS; pH 7.4)
containing 0.75 mM calcium chloride and 0.5 mM magnesium chloride
(CM-PBS), and incubated with 1 mL of vesiculation buffer for 2 h at 37C.
The vesiculation buffer consisted of CM-PBS with 25 mM formaldehyde,
0.5 mM 1,4-dithiotreitol (DTT), and a protease inhibitor cocktail (complete
mini EDTA-free tabs, Roche Applied Science). To quench the formaldehyde
after vesiculation, glycine solution in PBS was added to the vesiculation
buffer to a final concentration of 0.125 M. A large number of vesicles
were produced after 1.5 h, and the vesicles were transferred into four-well
Nunc (Penfield, NY) Lab-Tek II chambered coverslips for imaging.Fluorescence Image Acquisition
Vesicles were imaged using a Nikon (Melville, NY) Eclipse confocal laser
scanningmicroscope using a 60water-immersion objective.All the images
were collected and stored at 512 512 resolution. Three different scanswere
performed for each vesicle: 1), excitation at 488 nm, with a 500–530-nm
emission filter (donor scan); 2), excitation at 488 nm, with a 565–615-nm
emission filter (FRET scan); and 3), excitation at 543 nm, with a 650-nm
longpass filter (acceptor scan). Gains of 8.0 and pixel dwell time of 1.68
ms were used for the three scans. To minimize the bleaching of fluorescent
proteins, ND8 filters were used during excitation with the 488-nm laser.RESULTS
To measure the dimerization propensities of wild-type
FGFR3 and the A391 mutant, we cotransfected HEK293T
cells with 3 mg DNA encoding either 1) the wild-type
FGFR3 construct tagged with EYFP or mCherry, or 2), the
mutant FGFR3 construct tagged with EYFP or mCherry
(see Fig. 1). The dimerization of the wild-type construct has
been characterized previously in a different cell line, CHO
cells (26). Here, five independent experiments were per-
formed in a human cell line, HEK293T cells, and in each
experiment, the wild-type and the mutant were studied in
parallel.Fluorescent protein
Fluorescent protein
FIGURE 1 The receptor constructs used in the
experiments. The wild-type FGFR3 construct con-
sisted of 1), the signal peptide (SP), the extracel-
lular domain (EC), the transmembrane domain
(TM), a (GGS)5 unstructured linker, and a fluores-
cent protein, either EYFP or mCherry (a FRET
pair). The A391E mutation in the TM domain is
shown in red.
FGFR3 Dimerization 167After transfection, vesicles were produced by incubating
HEK293T cells with the vesiculation buffer, as described
in Materials and Methods and in previous publications
(see Fig. 2). Each vesicle was imaged in three different
scans, the donor, FRET, and acceptor scans. The donor
scan served to excite EYFP at 488 nm and to collect
EYFP emission in the range 500–530 nm. The acceptor
scan was used to excite the acceptor at 543 nm, and its
emission spectrum was collected in the range >650 nm.
For the FRET scan, EYFP was excited and the emission
of mCherry was collected in the range 565–615 nm. The
imaged vesicles exhibited uniform fluorescence intensities,
which allowed us to determine the concentrations of the
fluorescent proteins in the membrane using solutions of pu-
rified EYFP and mCherry of known concentration (26,31).
The fluorescent protein solutions were prepared as
described previously (31). The solutions were imaged in
the microscope using the same settings as above, to allow
direct comparison of solution and vesicle intensities.
Each vesicle was analyzed using a Matlab program to
determine the fluorescence intensity across the membrane
(26,31), which was fitted to a Gaussian function and the
background intensity was approximated as an error func-
tion. The donor, acceptor, and FRET intensities for each
vesicle were used to determine 1), the donor concentration,
2), the acceptor concentration, and 3), the FRET efficiency
in each vesicle, as described in detail elsewhere (26,31).
Briefly, for each vesicle, the concentration of the acceptor-
labeled proteins, CA, and the concentration of the donor-
labeled proteins, CD, per unit area were obtained using the
equations
CA ¼ IA
iA
(1)ID þ GFðIFRET  bDID  bAIAÞCD ¼
iD
: (2)The parameters iD and iA in Eqs. 1 and 2 are given by the
slopes of the fluorescence-intensity-versus-concentration
linear calibration curves for the soluble donor and acceptor,
respectively. The parameters bD and bA are the donor and
acceptor bleed-through coefficients, obtained by imaging
the purified EYFP and mCherry solutions as described
elsewhere (31). The intensities ID, IFRET, and IA are the
intensities measured for each vesicle in the donor, FRET,
and acceptor channels, as described above. The gauge
factor, GF, was obtained by analyzing vesicles loaded
with a soluble linked EYFP-mCherry construct (31). As
discussed previously (31), the gauge factor relates the
sensitized emission of the acceptor to the quenching of
the donor.
The FRET efficiency for each vesicle is calculated as
E ¼ 1 ID
ID þ GFðIFRET  bDID  bAIAÞ
(3)
The raw FRET efficiencies are plotted as a function of
acceptor concentration in Fig. 3. About 500 vesicles were
imaged for each construct in five independent experiments.
Each data point in Fig. 3 corresponds to a single vesicle.
Each independent experiment yielded ~100 data points for
the wild-type and 100 data points for the mutant. The results
from the independent experiments were indistinguishable
(p > 0.1).
In Fig. 3, the FRET efficiencies for the mutant are higher
than the FRET efficiencies measured for the wild-type. To
calculate and compare the dimerization propensities,
however, we also need to take into account the donor con-
centration for each point. Furthermore, we need to take
into account that unlike soluble proteins, membrane proteins
are confined to two-dimensional membranes. Thus, the fluo-
rescent proteins can come into close proximity to each other
(within 100 A˚) and FRET can occur even in the absence of
specific protein-protein interactions. This so-called random
FRET is well accounted for by a model developed byFIGURE 2 (A) A vesicle budding off from a
HEK293T cell. (B) A vesicle co-expressing EYFP
and mCherry-tagged FGFR3. Vesicles in the size
range 10–40 mm in diameter were imaged and
analyzed as described in Materials and Methods.
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FIGURE 3 FRET data for wild-type FGFR3 and the A391 mutant con-
structs as a function of acceptor concentration. Each of the ~1000 data
points represents a single vesicle for which the FRETefficiency, donor con-
centration, and acceptor concentration are determined using the quantita-
tive-imaging FRET method. Black solid squares and red open circles
indicate the FRET efficiencies measured for the wild-type and mutant con-
structs, respectively. Data scatter in this type of experiment is due to random
noise in image acquisition, and is reducible by collecting a large number of
data points (36). The solid line shows the so-called called random FRET,
which occurs if there are no specific interactions between the membrane
proteins; this phenomenon is well described by the model of Wolber and
Hudson (40).
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FIGURE 4 (A and B) Binned dimeric fractions as a function of the total
receptor concentration, and their standard deviations, for wild-type (A) and
the A391E mutant (B). The data were fitted to the dimerization model given
by Eqs. 5–7 (solid lines), yielding the dimerization constants, KD. The free
energies of dimerization were calculated as3.0 kcal/mol for the wild-type
and 4.5 kcal/mol for the A391E mutant. (C) Comparison of dimerization
propensities of wild-type FGFR3 (black solid squares) and the A391E
mutant (red open circles). In (C) we show binned data with their standard
errors. The dimerization constant increases 13 times due to the mutation,
and the stability of the FGFR3 dimer increases by 1.5 kcal/mol. (Insets)
Data and model predictions are replotted on a semilog scale.
168 Sarabipour and HristovaWolber and Hudson (40), as previously described (41–43),
and is shown with the solid line in Fig. 3. The model of
Wolber and Hudson has been verified experimentally in pre-
vious work (41). In particular, it has been demonstrated that
this random contribution can be measured directly for sim-
ple transmembrane helices labeled with organic dyes in lipid
bilayers using a fluorescence-lifetime approach, and that the
experimental data follow the theoretical prediction (41). In
addition, the proximity FRET measured for fluorophores
attached to lipids in vesicles is also very well predicted by
the model of Wolber and Hudson (44). This random-
FRET contribution therefore needs to be subtracted from
the measured FRETefficiency to obtain the FRETefficiency
due to sequence-specific interactions, ED.
Next, we calculate the dimeric fraction (i.e., the fraction
of receptors that are dimeric) in each vesicle, using the equa-
tion (43,45)
f ¼ ED
xAE
; (4)
where xA is the fraction of proteins tagged with the acceptor
and E is the FRET efficiency in a dimer containing a donor
and an acceptor. Here, as in previous work (36), the fluores-
cent proteins are attached to the TM domains via a 15-
amino-acid (GGS)5 flexible linker (46). The attachment of
the fluorescent proteins to the TM domains via the (GGS)5
flexible linker has been used in previous studies of GpA
dimerization (36), where E for this attachment was deter-
mined as E ¼ 0.635 0.04, corresponding to a 48.5-A˚ sep-
aration distance between the two fluorophores in the dimer.Biophysical Journal 105(1) 165–171With xA and E known, the dimeric fractions in each vesicle
were calculated from Eq. 4 and then averaged within bins of
total protein concentration of width 5  104 molecules/
nm2. The averaged dimeric fractions, along with the
standard deviations, are shown in Fig. 4, A and B, for the
wild-type and the mutant, respectively. Fig. 4 C compares
the averaged dimeric fractions and their standard errors.
FGFR3 Dimerization 169A two-state model describing receptor dimerization was
used to fit the experimental dimeric fractions and calculate
the dimerization constants. The reaction scheme describing
dimerization is given by Eq. 5,
M þM4KD D; (5)
where the dimerization constant is
KD ¼ ½D½M2; (6)
and the total concentration is given by
½T ¼ ½M þ 2½D: (7)
Using Eqs. 5–7, we can predict the dimeric fraction, f ¼ 2
[D]/[T], as a function of the total concentration, [T], for
any value of the dimerization constant, KD. Then, the value
of KD is optimized using a Matlab code such that the predic-
tion gives the best fit to the single-vesicle dimeric fractions
(before binning) while optimizing for the dimerization
constant, KD. The optimal KD values were 145 5 30 and
18905 380 nm2 for the wild-type and the mutant, respec-
tively. The errors correspond to the 95% confidence
intervals. The fits are shown in Fig. 4 by solid lines,
allowing a direct comparison between the binned data and
the fits.
The statistical significance of the mutation-induced
increase in dimerization can be determined using the stan-
dard errors for each data point (shown in Fig. 4 C) and
chi-squared analysis as described (34). The analysis yielded
a chi-squared value of 56.26 and a p-value of 0.001,
indicative of very high statistical significance. Thus, the
statistical analysis demonstrates that the mutation induces
a significant, measurable increase in dimeric fractions.
Defining the standard state as Kst ¼ 1 nm2, we can
calculate the free energy of dimer formation according to
DG ¼ RT ln

KD
Kst

(8)
Using Eq. 8, we obtain 3.0 5 0.1 kcal/mol for the wild-
type and 4.5 5 0.1 kcal/mol for the mutant. Thus, the
mutation stabilizes the dimer by 1.5 5 0.2 kcal/mol.DISCUSSION
Here we measured the difference in dimerization between a
wild-type FGFR3 construct and an A391E mutant FGFR3
construct, with kinase domains substituted with fluorescent
proteins for FRET detection. As the genes encoding for
these proteins were introduced into mammalian cells, the
RTK constructs were produced, folded, glycosylated, and
trafficked to the plasma membrane by the endogenous
cellular machinery. Upon vesiculation, the RTKs were local-ized in the membrane such that their interaction strength
could be quantified in the vesicles without the need for their
extraction, purification, and reconstitution (16,26). Thus, the
methodology used here is unique and useful, as it allows us
to calculate dimerization free energies for complex glycosy-
lated proteins in the plasma membrane.
Yet, in these experiments we are limited to membrane
proteins that can be correctly processed by the cellular
machinery of the cell line that we use. For instance, we
discovered that a mutant RTK construct with a deleted EC
domain does not localize to the membranes, despite the
fact that the signal peptide is present in the gene, and despite
the fact that a similar truncated wild-type construct ex-
hibited proper membrane localization in CHO cells (26).
The vesicles in the case of the mutant lacking the EC
domain exhibited uniform fluorescence throughout the
vesicle interior, and no membrane fluorescence. This
behavior has been observed for water-soluble fluorescent
proteins (31) and is indicative of a membrane insertion defi-
ciency via a mechanism that is currently unknown. Thus, we
could not quantify the effect of the mutation in the absence
of the EC domain in plasma membrane-derived vesicles.
However, the results in the presence of the EC domain,
shown here, can be directly compared to previous results
for the isolated FGFR3 TM domains in model lipid bilayers
(21). Although both experiments utilized FRET for detec-
tion of interactions, these two experiments are in fact very
different: In one case, synthetic TM helices labeled with
organic dyes were used and their interactions were charac-
terized in lipid bilayers. In the other case, glycosylated
receptors linked to fluorescent proteins at their C terminus
were expressed in mammalian cells and their interactions
were measured in vesicles derived from the plasma mem-
brane. The exact value of the dimerization free energy,
DG, depends on the definition of the standard free energy
in each environment and is expected to depend on the exact
protein sequence used in each experiment. It will further
depend on the degree of macromolecular crowding in the
plasma membrane-derived vesicles. Thus, it is not clear
whether the dimer stability measurements in the two envi-
ronments can be directly compared. The values of DDG,
on the other hand, do not depend on the exact definition
of the standard free energy, as in both environments DDG
represents the effect of the mutation on dimerization. There-
fore, the values of DDG that we measure in vesicles and in
plasma membrane-derived vesicles can be compared
directly without the need for any assumptions. The two
very different experiments yielded the same contribution
of the A391E mutation to dimer stability: 1.3 5 0.2
and 1.5 5 0. 2 kcal/mol. It therefore appears that the
presence of the large EC domain does not prevent the
Glu391-mediated interactions that lead to the increase in
dimer stability.
The TM domains of wild-type FGFR3 and the A391E
mutant have been shown to form sequence-specific dimersBiophysical Journal 105(1) 165–171
170 Sarabipour and Hristova(21). In a published model of the wild-type TM domain
dimer, which has been experimentally verified using NMR
(47), the two wild-type TM helices pack tightly into a
knob-into-hole configuration, and the dimer is stabilized
via van der Waals interactions. Although there is no
structure for the mutant dimer, the wild-type dimer structure
is consistent with the idea that each Glu residue in
the A391E mutant can form a hydrogen bond with the
neighboring helix (21). Therefore, the increase in dimer
stability that we measure in the presence and in the absence
of the extracellular domain is likely due to the formation
of hydrogen bonds between the TM helices in the
membrane.
The environment that the proteins explore in the model
lipid bilayers is distinctly different from the one they explore
in the plasma membrane-derived vesicles, because the
vesicles contain diverse lipids and proteins that are found
in the plasma membrane of mammalian cells. Questions
may therefore arise as to why the strength of the hydrogen
bonds is the same in the two different environments. There
are a few measurements of the contribution of side-chain
hydrogen bonds to the stability of tertiary and quaternary
membrane protein structures, all of them in model lipid
bilayers, and they show that the side-chain hydrogen-bond
strength is very modest, ~1 kcal/mol (21,39,48,49). This
strength is much weaker than expected based on measure-
ments in organic solvent and on calculations (50,51), and it
is similar to the values observed in soluble proteins
(52–56). To rationalize these results, it has been argued that
the membrane protein itself can provide ‘‘a rich source of
competitive hydrogen bonds and a polarizable environment
that can weaken hydrogen bonds,’’ thus likely eliminating
the effect of the environment on hydrogen-bond strength
(39). As the hydrogen-bond strength has been shown to be
the same in lipid bilayers and in water, it is not surprising
that the strength is the same in model bilayers and in plasma
membrane-derived vesicles.
Until structures of full-length receptor dimers become
available, we will likely not know with certainty whether
the TM helices in full-length RTKs interact intimately or
whether their close approach is hindered by the large soluble
RTK domains. Questions therefore arise as to whether the
numerous studies of isolated RTK TM domains lead to
better understanding of RTK signaling. Here we use thermo-
dynamicmeasurements as a tool to gain some insight into this
problem. The fact that we observe the same effect of the
A391E mutation on the stability of both isolated TM domain
dimers and glycosylated FGFR3 dimers suggests that the
interactions that we observe in the simple TM peptide model
systems are highly relevant in a biological context.We thank Drs. Edwin Li and Lijuan He, and Mr. Jesse Placone for many
helpful discussions.
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